Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: The AGITG ATTAX trial.

MLA

Van Hazel G., et al. Randomised, Non-Comparative Phase II Study of Weekly Docetaxel with Cisplatin and 5-Fluorouracil or with Capecitabine in Oesophagogastric Cancer: The AGITG ATTAX Trial. 2012. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305130633&authtype=sso&custid=ns315887.

APA

Van Hazel G., Strickland A., Ganju V., Zalcberg J., Gebski V., Stockler M., Gibbs D., Tebbutt N.C., Cummins M.M., & Sourjina T. (2012). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: The AGITG ATTAX trial.

Chicago

Van Hazel G., Strickland A., Ganju V., Zalcberg J., Gebski V., Stockler M., Gibbs D., Tebbutt N.C., Cummins M.M., and Sourjina T. 2012. “Randomised, Non-Comparative Phase II Study of Weekly Docetaxel with Cisplatin and 5-Fluorouracil or with Capecitabine in Oesophagogastric Cancer: The AGITG ATTAX Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305130633&authtype=sso&custid=ns315887.